GO:0015879 carnitine transport: Fatty Acid Oxidation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015879 carnitine transport describes the directed movement of carnitine into, out of, or within a cell, or between cells, by means of a transporter or pore.
• Carnitine is essential for transferring long-chain acyl groups across the inner mitochondrial membrane for fatty acid oxidation.
• The plasma membrane sodium-dependent carnitine transporter OCTN2 (SLC22A5) is the primary mediator of cellular carnitine uptake.
• The mitochondrial carnitine acyl-carnitine carrier (SLC25A20) mediates the exchange of acylcarnitines and carnitine across the inner mitochondrial membrane.
• Defects in carnitine transport cause primary carnitine deficiency, a treatable disorder presenting with cardiomyopathy, hypoglycemia, and muscle weakness [3,6].
• Carnitine transport is critical in tissues with high fatty acid oxidation demands, including heart, skeletal muscle, liver, and brain [2,4,7].
Description
Carnitine transport (GO:0015879) is the biological process responsible for the directed movement of carnitine into, out of, or within a cell, or between cells, via transporters or pores. Carnitine is a hydrophilic compound that cannot freely diffuse across lipid bilayers; therefore, specific transport proteins are required to deliver it to cellular compartments where it participates in fatty acid oxidation and acyl group buffering. The process is essential for energy homeostasis, particularly in tissues that rely heavily on fatty acid oxidation such as cardiac and skeletal muscle [2,7]. At the cellular level, carnitine transport encompasses uptake across the plasma membrane and transport across the inner mitochondrial membrane. The sodium-dependent organic cation transporter OCTN2 (SLC22A5) mediates high-affinity carnitine uptake into cells. Inside the cell, the mitochondrial carnitine acyl-carnitine carrier (CAC, SLC25A20) exchanges carnitine for acylcarnitines across the inner mitochondrial membrane, a step required for the carnitine shuttle and fatty acid oxidation. In the brain, carnitine transport supports additional roles in acetyl-CoA buffering and neurotransmitter metabolism. Research on carnitine transport is clinically important because inherited defects in transport proteins cause primary carnitine deficiency, a disorder with potentially severe cardiac and metabolic consequences that can be treated with carnitine supplementation [3,6,8]. Understanding the molecular mechanisms, regulation, and tissue-specific roles of carnitine transporters is therefore critical for diagnosis, therapy, and the development of targeted experimental models [1,8].
carnitine transport At A Glance
| GO ID | GO:0015879 |
|---|---|
| GO term | carnitine transport |
| Ontology | biological_process |
| Synonym | vitamin Bt transport |
| Major function | Mediates the movement of carnitine across cellular and mitochondrial membranes to support fatty acid oxidation and acyl group transfer |
| Key transporters | SLC22A5 (OCTN2) at the plasma membrane; SLC25A20 (CAC) at the inner mitochondrial membrane [3,5] |
| Tissue distribution | High in heart, skeletal muscle, liver, kidney, and brain [2,4,7] |
| Related disorders | Primary carnitine deficiency, cardiomyopathy, hypoglycemia, muscle weakness [3,6,8] |
What Is GO:0015879?
Carnitine transport (GO:0015879) is defined as the directed movement of carnitine into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. Carnitine is a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane.
Why Is carnitine transport Important in Cell Biology?
Carnitine transport is fundamental for energy metabolism because it supplies carnitine to the mitochondrial matrix, where it is required for the carnitine shuttle that transfers long-chain fatty acids for beta-oxidation. Without efficient transport, cells cannot oxidize fatty acids, leading to energy failure, accumulation of toxic acylcarnitines, and clinical manifestations such as cardiomyopathy and hypoglycemia [3,6]. The process is also relevant to drug transport, redox sensing, and brain metabolism, making it a broad area of biomedical research [4,5].
• Enables fatty acid oxidation by delivering carnitine to mitochondria.
• Defects cause primary carnitine deficiency, a treatable metabolic disorder [3,6].
• Critical for cardiac and skeletal muscle energy production [2,7].
• Involved in brain metabolism and acetyl-CoA homeostasis.
• SLC25A20 (CAC) is a target for drug interactions and redox regulation.
• Carnitine transport affects systemic carnitine levels and renal reabsorption.
• Provides a model for studying membrane transporter structure-function.
• Relevant to newborn screening and genetic diagnosis.
• Potential modifier of metabolic syndrome and muscle performance.
• Links to mitochondrial disease and acyl-carnitine profiling [1,6].
What Happens During carnitine transport?
Uptake across the plasma membrane
In simple terms: Carnitine is brought into the cell from the blood by a specific transporter.
The sodium-dependent organic cation transporter OCTN2 (SLC22A5) mediates high-affinity carnitine uptake at the plasma membrane. This transporter couples carnitine movement to the sodium gradient, allowing cells to accumulate carnitine against its concentration gradient. Tissues with high fatty acid oxidation demands, such as heart and skeletal muscle, express high levels of OCTN2 to ensure adequate carnitine supply [2,7].
Intracellular trafficking and compartmentalization
In simple terms: Once inside, carnitine is distributed to different parts of the cell where it is needed.
After uptake, carnitine is available in the cytosol and can be transported into mitochondria. The mitochondrial carnitine acyl-carnitine carrier (CAC, SLC25A20) exchanges cytosolic carnitine for acylcarnitines across the inner mitochondrial membrane. This exchange is essential for the carnitine shuttle, which transfers long-chain fatty acyl groups from the cytosol to the mitochondrial matrix for beta-oxidation. In the brain, carnitine transport also supports acetyl-CoA buffering and neurotransmitter synthesis.
Mitochondrial carnitine shuttle
In simple terms: Carnitine acts as a shuttle to move fatty acids into the mitochondria to be burned for energy.
The carnitine shuttle involves sequential actions of carnitine palmitoyltransferases (CPT1 and CPT2) and the carnitine acyl-carnitine carrier (CAC). CPT1 attaches acyl groups to carnitine, forming acylcarnitines that are transported by CAC into the mitochondrial matrix, where CPT2 releases carnitine and acyl-CoA for beta-oxidation. The transport step mediated by CAC is rate-limiting and subject to regulation by redox state and drugs.
Efflux and systemic carnitine homeostasis
In simple terms: Carnitine can also leave cells, and the body balances its levels through the kidneys.
Carnitine transport is bidirectional; efflux from cells contributes to plasma carnitine pools. The kidney reabsorbs carnitine via OCTN2, and defects in this transporter lead to urinary carnitine wasting and systemic carnitine depletion [3,8]. This systemic homeostasis is critical for maintaining adequate carnitine for all tissues.
Key Genes Involved in GO:0015879 carnitine transport
The following genes encode proteins directly involved in carnitine transport and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC22A5 | Plasma membrane sodium-dependent carnitine transporter (OCTN2) | Primary carnitine deficiency; drug transport; renal reabsorption |
| SLC25A20 | Mitochondrial carnitine acyl-carnitine carrier (CAC) | Fatty acid oxidation; redox sensing; drug interactions |
| CPT1A | Carnitine palmitoyltransferase 1A, generates acylcarnitines for transport | Regulation of fatty acid oxidation; carnitine shuttle |
| CPT1B | Muscle isoform of CPT1 | Muscle fatty acid oxidation; carnitine transport demand |
| CPT2 | Carnitine palmitoyltransferase 2, releases carnitine in mitochondria | Fatty acid oxidation; carnitine recycling |
| SLC25A29 | Mitochondrial carnitine/acylcarnitine carrier-like protein | Amino acid and carnitine transport; less characterized |
| SLC22A4 | Organic cation transporter, may transport carnitine | Drug transport; potential redundancy |
| SLC22A16 | Carnitine transporter in testis and other tissues | Fertility; carnitine transport |
| PPARA | Regulates expression of fatty acid oxidation genes | Transcriptional control of carnitine transport components |
| PPARGC1A | Coactivator regulating mitochondrial biogenesis and fatty acid oxidation | Energy metabolism; carnitine transport capacity |
| Nrf2 (NFE2L2) | Redox-sensitive transcription factor | Regulates antioxidant response and possibly carnitine transport |
| SLC25A20 mutations | Cause carnitine-acylcarnitine translocase deficiency | Neonatal cardiomyopathy; hypoglycemia |
| SLC22A5 mutations | Cause primary carnitine deficiency | Cardiomyopathy; muscle weakness; hypoglycemia |
| CACT (SLC25A20) | Same as SLC25A20 | Mitochondrial carnitine transport |
| OCTN1 (SLC22A4) | Organic cation/carnitine transporter | Inflammation; drug transport |
| OCTN3 (SLC22A16) | Carnitine transporter | Testis; carnitine homeostasis |
| Carnitine palmitoyltransferase 1C (CPT1C) | Brain-specific CPT1 | Brain carnitine metabolism |
How Is carnitine transport Regulated?
Carnitine transport is regulated at multiple levels. The expression of SLC22A5 (OCTN2) is controlled by transcription factors such as PPAR alpha and possibly Nrf2, linking transport capacity to fatty acid oxidation demand and redox status [1,5]. The mitochondrial carrier SLC25A20 (CAC) is regulated by redox sensing through critical cysteine residues, and its activity can be modulated by drugs and metabolites. Hormonal and metabolic signals, such as insulin and fasting, also influence carnitine transport and fatty acid oxidation flux. In the brain, carnitine transport may be regulated by energy status and neurotransmitter demand.
carnitine transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC22A5 | Primary carnitine deficiency; cardiomyopathy; hypoglycemia | Knockout mouse; patient-derived iPSC-cardiomyocytes; point mutation knock-in |
| SLC25A20 | Carnitine-acylcarnitine translocase deficiency; neonatal cardiomyopathy | Knockout mouse; CRISPR point mutation in cell lines |
| CPT1A | CPT1A deficiency; hypoketotic hypoglycemia | Liver-specific knockout; knock-in of patient mutations |
| CPT2 | CPT2 deficiency; myopathy; rhabdomyolysis | Muscle-specific knockout; point mutation knock-in |
| SLC22A4 | Inflammatory bowel disease; drug transport | Knockout cell lines; overexpression |
Primary carnitine deficiency
Primary carnitine deficiency is an autosomal recessive disorder caused by mutations in SLC22A5, which encodes the plasma membrane carnitine transporter OCTN2. Loss of function leads to reduced cellular carnitine uptake, urinary carnitine wasting, and systemic carnitine depletion. Clinically, it presents with cardiomyopathy, hypoglycemia, muscle weakness, and Reye-like episodes, but it is treatable with high-dose carnitine supplementation [3,8].
Carnitine-acylcarnitine translocase deficiency
Mutations in SLC25A20, encoding the mitochondrial carnitine acyl-carnitine carrier (CAC), cause carnitine-acylcarnitine translocase deficiency, a severe disorder of fatty acid oxidation. Affected individuals typically present in infancy with hypoketotic hypoglycemia, cardiomyopathy, and hyperammonemia, often with poor outcomes. This highlights the critical role of mitochondrial carnitine transport in energy metabolism.
Carnitine transport in brain and neurological disorders
Carnitine transport in the brain is important for acetyl-CoA buffering and neurotransmitter metabolism, and alterations have been implicated in neurological conditions such as epilepsy and neurodegeneration. However, the exact roles and therapeutic potential remain under investigation.
Cardiac and skeletal muscle disorders
Because heart and skeletal muscle rely heavily on fatty acid oxidation, defects in carnitine transport can lead to cardiomyopathy and muscle weakness [2,7]. Carnitine transport capacity is also relevant to exercise performance and muscle metabolism.
From carnitine transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC22A5 impair carnitine uptake and fatty acid oxidation? | SLC22A5 knockout cell line (e.g., HEK293, HeLa) |
| What is the effect of a specific patient mutation on OCTN2 function? | Point mutation knock-in via CRISPR in cell lines |
| Can carnitine transport be restored by wild-type SLC22A5? | Knock-in of tagged SLC22A5 for rescue and localization |
| Does overexpression of SLC25A20 enhance mitochondrial fatty acid oxidation? | SLC25A20 overexpression in cardiomyocytes or hepatocytes |
| What are the tissue-specific roles of carnitine transport in vivo? | Tissue-specific knockout mouse models (heart, muscle, liver) |
| Can CRISPR screening identify modifiers of carnitine transport? | Genome-wide CRISPR knockout library screening in carnitine-dependent cells |
How to Study the carnitine transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled carnitine uptake | Transport rate and kinetics | Characterization of OCTN2 and CAC function |
| Acylcarnitine profiling (MS/MS) | Levels of acylcarnitines in blood or cells | Diagnosis of carnitine transport defects |
| Fatty acid oxidation flux assay | Oxidation of labeled fatty acids | Functional assessment of carnitine shuttle |
| CRISPR knockout | Loss-of-function phenotype | Determining gene requirement for carnitine transport |
| CRISPR knock-in | Expression of mutant or tagged protein | Modeling patient mutations |
| Overexpression | Gain-of-function effects | Testing sufficiency of transporters |
| Western blot | Protein expression levels | Validation of knockout or overexpression |
| Immunofluorescence | Subcellular localization | Trafficking and organelle targeting |
Transport assays
Radiolabeled carnitine uptake assays in cultured cells or isolated membrane vesicles are used to measure transport kinetics and specificity. These assays can be performed in knockout or mutant cell lines to determine the contribution of specific transporters.
Genetic and molecular techniques
CRISPR-Cas9 knockout, point mutation knock-in, and overexpression are used to dissect the function of carnitine transporters [3,5]. Sanger sequencing and next-generation sequencing validate edits, while qPCR and western blot confirm expression levels.
Metabolic and flux analysis
Acylcarnitine profiling by tandem mass spectrometry and fatty acid oxidation flux assays using radiolabeled palmitate measure the functional consequences of altered carnitine transport. Seahorse extracellular flux analysis can assess mitochondrial respiration.
Imaging and localization
Fluorescently tagged transporters (e.g., GFP-SLC22A5) and immunofluorescence microscopy reveal subcellular localization and trafficking. Live-cell imaging can monitor transport dynamics.
How CRISPR Can Be Used to Study GO:0015879 carnitine transport
Knockout
CRISPR knockout of SLC22A5 or SLC25A20 in cell lines abolishes carnitine transport, providing a clean background to study transport mechanisms and compensatory pathways [3,5]. Knockout models are also used to confirm drug specificity and to identify off-target effects.
Point Mutation
Point mutations identified in patients with primary carnitine deficiency or CAC deficiency can be introduced into cell lines using CRISPR base editing or homology-directed repair to assess their impact on transport activity and protein stability [3,5].
Knock-in
Knock-in of tagged versions of SLC22A5 or SLC25A20 (e.g., GFP or HA tags) allows real-time tracking of transporter localization and dynamics in live cells. Knock-in of wild-type alleles can rescue knockout phenotypes and confirm causality.
Overexpression
Overexpression of carnitine transporters via CRISPR activation or lentiviral delivery increases transport capacity and can be used to study gain-of-function effects on fatty acid oxidation and cellular metabolism.
How EDITGENE Supports carnitine transport Research
Researchers studying carnitine transport-related genes often need to determine whether a candidate gene is causally involved in carnitine uptake, mitochondrial fatty acid oxidation, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to create precisely engineered cell models that enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for carnitine transport research.
Frequently Asked Questions About carnitine transport
What is carnitine transport?
Carnitine transport (GO:0015879) is the directed movement of carnitine into, out of, or within a cell, or between cells, by means of a transporter or pore.
What genes are involved in carnitine transport?
Key genes include SLC22A5 (OCTN2) for plasma membrane uptake and SLC25A20 (CAC) for mitochondrial transport, as well as CPT1A, CPT1B, and CPT2 for the carnitine shuttle [1,3,5].
What is the function of carnitine transport?
It supplies carnitine to cells and mitochondria, enabling the transfer of long-chain acyl groups for fatty acid oxidation and energy production.
What diseases are associated with defective carnitine transport?
Primary carnitine deficiency (SLC22A5 mutations) and carnitine-acylcarnitine translocase deficiency (SLC25A20 mutations) are the main disorders, presenting with cardiomyopathy, hypoglycemia, and muscle weakness [3,5,6].
How is carnitine transported into mitochondria?
The mitochondrial carnitine acyl-carnitine carrier (CAC, SLC25A20) exchanges cytosolic carnitine for acylcarnitines across the inner mitochondrial membrane.
What is the role of SLC22A5 in carnitine transport?
SLC22A5 encodes OCTN2, a sodium-dependent carnitine transporter that mediates high-affinity uptake at the plasma membrane and renal reabsorption.
Can carnitine transport be studied with CRISPR?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to dissect the function of carnitine transporters and model related diseases [3,5].
What are the symptoms of primary carnitine deficiency?
Symptoms include cardiomyopathy, hypoglycemia, muscle weakness, fatigue, and Reye-like episodes, often triggered by fasting or illness [3,6].
How is carnitine transport regulated?
It is regulated by transcription factors such as PPAR alpha, redox status affecting SLC25A20, and hormonal signals like insulin [1,5].
What methods measure carnitine transport?
Radiolabeled uptake assays, acylcarnitine profiling by mass spectrometry, and fatty acid oxidation flux assays are commonly used [1,3].
Conclusion
Carnitine transport (GO:0015879) is a vital biological process that ensures carnitine availability for fatty acid oxidation and cellular energy homeostasis. The plasma membrane transporter OCTN2 (SLC22A5) and the mitochondrial carrier CAC (SLC25A20) are central players, and their dysfunction leads to severe metabolic disorders such as primary carnitine deficiency and carnitine-acylcarnitine translocase deficiency [3,5]. Continued research using CRISPR-engineered models will further elucidate the molecular mechanisms and therapeutic opportunities targeting carnitine transport [1,8].
References
- 1. Longo N et al.. 2016. Carnitine transport and fatty acid oxidation.. Biochim Biophys Acta 1863(10):2422-35 PMID: 26828774
- 2. Siliprandi N et al.. 1987. Myocardial carnitine transport.. Basic Res Cardiol 82 Suppl 1:53-62 PMID: 3311009
- 3. Frigeni M et al.. 2017. Functional and molecular studies in primary carnitine deficiency.. Hum Mutat 38(12):1684-1699 PMID: 28841266
- 4. Nałecz KA et al.. 2004. Carnitine: transport and physiological functions in the brain.. Mol Aspects Med 25(5-6):551-67 PMID: 15363641
- 5. Tonazzi A et al.. 2021. The Mitochondrial Carnitine Acyl-carnitine Carrier (SLC25A20): Molecular Mechanisms of Transport, Role in Redox Sensing and Interaction with Drugs.. Biomolecules 11(4) PMID: 33807231
- 6. Tein I. 2003. Carnitine transport: pathophysiology and metabolism of known molecular defects.. J Inherit Metab Dis 26(2-3):147-69 PMID: 12889657
- 7. Siliprandi N et al.. 1990. Transport and functions of carnitine in muscles.. J Clin Chem Clin Biochem 28(5):303-6 PMID: 2199594
- 8. Longo N et al.. 2006. Disorders of carnitine transport and the carnitine cycle.. Am J Med Genet C Semin Med Genet 142C(2):77-85 PMID: 16602102
